Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Alida C. Weidenaar, Arja ter Elst, PhD, Cees AGM van Montfort, PhD, Tiny G.J. Meeuwsen-de Boer, Stefano Rosati, MD, Mario Bargetzi, MD, Carlos Graux, MD, PhD, Alois Gratwohl, MD, PhD, Bob Lowenberg, MD, PhD, Gert Ossenkoppele, MD, PhD, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 1555.

https://doi.org/10.1182/blood.V118.21.1555.1555

Published: 2011

Journal Articles

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Alida C. weidenaar, Ajra ter Elst, PhD, Gineke Koopmans-Klein, Stefano Rosati, MD, Wilfred F.A. den Dunnen, MD, PhD, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps, MD, PhD, Edo Vellenga, MD, PhD, Evelina S.J.M. de Bont, MD, PhD

Blood (2010) 116 (21): 2712.

https://doi.org/10.1182/blood.V116.21.2712.2712

Published: 2010

Journal Articles

The Role of VEGFA in Malignant Progression in AML

Alida C Weidenaar, Arja ter Elst, Henk-Marijn de Jonge, Tiny Meeuwsen-de Boer, Willem A Kamps, Evelina S De Bont

Blood (2008) 112 (11): 203.

https://doi.org/10.1182/blood.V112.11.203.203

Published: 2008

Journal Articles

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Alida C. Weidenaar, Hendrik J.M. de Jonge, Vaclav Fidler, PhD, Arja ter Elst, PhD, Tiny Meeuwsen, Jenny Douwes, Jessica C.A. Bouma, PhD, Karel Hählen, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 4199.

https://doi.org/10.1182/blood.V110.11.4199.4199

Published: 2007

Journal Articles

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Hendrik J.M. de Jonge, Arja ter Elst, PhD, H. Marike Boezen, PhD, Alida C. Weidenaar, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, PhD, Gertjan J.L. Kaspers, MD/PhD, Bianca F. Goemans, MD, Ursula Creutzig, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S.J.M. de Bont, MD/PhD

Blood (2006) 108 (11): 838.

https://doi.org/10.1182/blood.V108.11.838.838

Published: 2006

NARROW

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

The Role of VEGFA in Malignant Progression in AML

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

The Role of VEGFA in Malignant Progression in AML

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only